UBS Asset Management Americas Inc. purchased a new stake in shares of Epizyme, Inc. (NASDAQ:EPZM) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,200 shares of the biopharmaceutical company’s stock, valued at approximately $175,000.

A number of other large investors have also bought and sold shares of EPZM. Metropolitan Life Insurance Co. NY raised its stake in Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,269 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Epizyme by 8.2% in the first quarter. Bank of New York Mellon Corp now owns 196,837 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 14,978 shares during the period. Russell Investments Group Ltd. increased its position in shares of Epizyme by 59.6% in the first quarter. Russell Investments Group Ltd. now owns 45,343 shares of the biopharmaceutical company’s stock worth $778,000 after buying an additional 16,924 shares during the period. State Street Corp increased its position in shares of Epizyme by 49.4% in the fourth quarter. State Street Corp now owns 1,088,635 shares of the biopharmaceutical company’s stock worth $13,173,000 after buying an additional 359,859 shares during the period. Finally, Norges Bank purchased a new position in shares of Epizyme during the fourth quarter worth $5,961,000. 81.63% of the stock is currently owned by institutional investors.

Epizyme, Inc. (NASDAQ:EPZM) opened at 14.15 on Friday. The stock’s market cap is $825.77 million. Epizyme, Inc. has a 52-week low of $7.02 and a 52-week high of $18.50. The company’s 50 day moving average is $13.86 and its 200-day moving average is $14.31.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.06. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 55.41%. The firm had revenue of $10 million during the quarter, compared to analyst estimates of $3.95 million. During the same quarter in the prior year, the business posted ($0.49) earnings per share. Epizyme’s revenue for the quarter was up 2027.7% compared to the same quarter last year. On average, equities analysts anticipate that Epizyme, Inc. will post ($2.42) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “10,200 Shares in Epizyme, Inc. (NASDAQ:EPZM) Acquired by UBS Asset Management Americas Inc.” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/08/05/10200-shares-in-epizyme-inc-nasdaqepzm-acquired-by-ubs-asset-management-americas-inc.html.

A number of brokerages have weighed in on EPZM. BidaskClub downgraded shares of Epizyme from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Tuesday, July 18th. ValuEngine upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Cann restated a “buy” rating and set a $26.00 price target on shares of Epizyme in a research report on Wednesday, June 21st. Finally, Leerink Swann restated an “outperform” rating and set a $31.00 price target on shares of Epizyme in a research report on Friday, June 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. Epizyme has a consensus rating of “Buy” and a consensus price target of $23.75.

In other news, insider Robert A. Copeland sold 2,500 shares of the company’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $13.45, for a total value of $33,625.00. Following the completion of the transaction, the insider now directly owns 34,038 shares in the company, valued at $457,811.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $16.11, for a total transaction of $241,650.00. Following the completion of the transaction, the insider now owns 22,228 shares of the company’s stock, valued at $358,093.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,524 shares of company stock valued at $746,797. 25.20% of the stock is owned by insiders.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme, Inc. (NASDAQ:EPZM).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.